Evidence map›Paper›PMID 33173007›Full record

ArticlemBio2020

A Targeted Computational Screen of the SWEETLEAD Database Reveals FDA-Approved Compounds with Anti-Dengue Viral Activity.

Jasmine Moshiri, David A Constant, Bowen Liu, Roberto Mateo, Steven Kearnes, Paul Novick, Ritika Prasad, Claude Nagamine, Vijay Pande, Karla Kirkegaard

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in mBio, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.

0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

6 citing papers in PubMed.

  1. Review
  2. Article
  3. A Recombinant Genotype I Japanese Encephalitis Virus Expressing aInternational journal of molecular sciences · 2022
    Article
  4. Article
  5. Dengue virus NS4B protein as a target for developing antivirals.Frontiers in cellular and infection microbiology · 2022
    Review
  6. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors.

Jasmine Moshiri *Department of Microbiology and Immunology, Stanford University School of Medicine, Stanford, California, USA.
David A Constant *Department of Microbiology and Immunology, Stanford University School of Medicine, Stanford, California, USA.
Bowen LiuDepartment of Chemistry, Stanford University, Stanford, California, USA.
Roberto MateoDepartment of Microbiology and Immunology, Stanford University School of Medicine, Stanford, California, USA.
Steven KearnesDepartment of Chemistry, Stanford University, Stanford, California, USA.
Paul NovickDepartment of Chemistry, Stanford University, Stanford, California, USA.
Ritika PrasadDepartment of Chemistry, Stanford University, Stanford, California, USA.
Claude NagamineDepartment of Comparative Medicine, Stanford University School of Medicine, Stanford, California, USA.
Vijay PandeDepartment of Chemistry, Stanford University, Stanford, California, USA pande@stanford.edu karlak@stanford.edu.
Karla KirkegaardDepartment of Microbiology and Immunology, Stanford University School of Medicine, Stanford, California, USA pande@stanford.edu karlak@stanford.edu.

Funding

Supplement to Enhance Wellness and Resiliency in the Graduate EnvironmentT32GM007276 · NIGMS · STANFORD UNIVERSITY · PI MORRISON, ASHBY J. · 1985 to 2023
$32.9M
Translational Incubator CoreU19AI109662 · NIAID · STANFORD UNIVERSITY · PI GLENN, JEFFREY S · 2014 to 2019
$28.6M
MOLECULAR BASIS OF HOST-PARASITE INTERACTIONT32AI007328 · NIAID · STANFORD UNIVERSITY · PI JUSTIN L SONNENBURG · 1987 to 2026
$11.9M
Viral use and mimicry of autophagy pathway and componentsR01AI134912 · NIAID · STANFORD UNIVERSITY · PI KIRKEGAARD, KARLA · 2018 to 2021
$1.6M
NIAID NIH HHS R01 AI134912NIAID NIH HHS T32 AI007328NIAID NIH HHS U19 AI109662NIGMS NIH HHS T32 GM007276
6 · The paper itself

Abstract

Affordable and effective antiviral therapies are needed worldwide, especially against agents such as dengue virus that are endemic in underserved regions. Many antiviral compounds have been studied in cultured cells but are unsuitable for clinical applications due to pharmacokinetic profiles, side effects, or inconsistent efficacy across dengue serotypes. Such tool compounds can, however, aid in identifying clinically useful treatments. Here, computational screening (Rapid Overlay of Chemical Structures) was used to identify entries in an

Indexed as

AnimalsAntiviral AgentsDatabases, PharmaceuticalDengueDengue VirusDrug Evaluation, PreclinicalDrug RepositioningHumansMiceMice, Inbred C57BLViral LoadVirus ReplicationAntiviral Agentsantiviral pharmacologycapsidcomputational biologydengue virusproteasesrepurposing

Identifiers

PMID33173007
PMCPMC7667029

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.